(Press-News.org) An experimental drug that blocks two points of a crucial cancer cell signaling pathway inhibits the growth of ovarian cancer cells and significantly increases survival in an ovarian cancer mouse model, a study at UCLA's Jonsson Comprehensive Cancer Center has found.
The drug, called NVP-BEZ235, also inhibits growth of ovarian cancer cells that have become resistant to the conventional treatment with platinum chemotherapy, and helps to re-sensitize the cancer cells to the therapy. It also enhances the effect of platinum chemotherapy on ovarian cancer cells that are still responding to the therapy, said Dr. Oliver Dorigo, an assistant professor of obstetrics and gynecology, a Jonsson Cancer Center researchers and senior author of the study.
"Platinum-based chemotherapy drugs are effective in treating ovarian cancers as long as the cancer cells remain sensitive to platinum," Dorigo said. "But once the tumor becomes resistant, treating the cancer becomes very challenging. This is a significant clinical problem, since the majority of ovarian cancer patients develop resistance at some point during treatment. Breaking chemotherapy resistance is a difficult challenge, but crucial if we want to improve long-term survival for our patients."
The study, performed on cells lines and mouse models, appears in the April 15, 2011 issue of the journal Clinical Cancer Research.
Dorigo has been working in his laboratory over the last several years in an effort to develop new therapies for ovarian cancer. About 22,000 American women are diagnosed with ovarian cancer, and more than 14,000 deaths are attributed to this disease every year. Dorigo has focused his research efforts on a pathway called PI3Kinase/Akt/mTOR, which once activated promotes ovarian cancer growth. The activated pathway also makes the cancer more aggressive and more likely to spread to other organs, Dorigo said, so targeting it offers great promise for more effective therapies for the disease.
In this two-year study, Dorigo and postdoctoral fellow Chintda Santiskulvong found that inhibiting two checkpoints of the pathway - PI3Kinase and mTOR - with NVP-BEZ235 decreased cancer growth, both in cell culture dishes and in mice with ovarian cancer. It also significantly increased survival in the mice, he said. More importantly, NVP-BEZ235 slowed growth of the ovarian cancer cells that had become resistant to platinum and helped to break that resistance.
"We were very encouraged to find that NPV-BEZ235 could re-sensitize the ovarian cancer cells to standard platinum treatment," Dorigo said. "In addition, we found this drug to be more effective in inhibiting ovarian cancer cell growth than other drugs that target only one checkpoint, mTOR, in this pathway. We believe that NVP-BEZ235 has superior efficacy because of the dual effect on PI3Kinase and mTOR."
The experimental drug is being tested as a single agent at the Jonsson Cancer Center in human clinical trials against other solid tumors. Researchers involved with those studies have said early results are encouraging.
"This is clearly a promising agent with activity in humans," said Dr. John Glaspy, a professor of hematology/oncology and a Jonsson Cancer Center scientist involved with the studies. "We are still assessing its tolerability in patients."
Dorigo said he hopes to initiate a clinical trial for women with ovarian cancer that tests the combination of NVP-BEZ235 with platinum chemotherapy, as he believes that the combination might be more effective than each drug alone. .
###
The study was funded by the Ovarian Cancer Research Foundation/Liz Tilberis Scholarship, the Gynecologic Cancer Foundation/Florence & Marshall Schwid Ovarian Cancer Award, a STOP Cancer Career Development Award and the National Institutes of Health Women's Reproductive Health Research Program.
UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2010, the Jonsson Cancer Center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 10 of the last 11 years. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.
Experimental drug inhibits cell signaling pathway and slows ovarian cancer growth
Drug also increases sensitivity to chemotherapy, may help fight drug resistance, study finds
2011-04-15
ELSE PRESS RELEASES FROM THIS DATE:
Safety of stored blood among chief concerns for transfusion medicine community
2011-04-15
In light of recent studies that suggest the use of stored blood during transfusions may cause adverse effects in patients, the National Heart, Lung, and Blood Institute (NHLBI) funded a number of research projects to examine the safety of transfusing older red cells and the impact of stored blood on respiratory gases. These papers discussing potential adverse effects of stored blood and related concerns for oxygen delivery by transfusion are now available online in TRANSFUSION, a journal published by Wiley-Blackwell on behalf of AABB.
Blood banks are responsible for ...
Genital herpes more virulent in Africa than in US
2011-04-15
BOSTON, Mass. (April 15, 2011) — Strains of genital herpes in Africa are far more virulent than those in the United States, researchers at Harvard Medical School report, a striking insight into a common disease with important implications for preventing HIV transmission in a region staggered by the HIV/AIDS epidemic. The researchers arrived at this finding by testing mouse model strains of the disease against vaccine candidates. All vaccines were far more efficacious in abating the U.S. strain.
The researchers say identification of the properties of the African viruses ...
Jefferson researchers unlock key to personalized cancer medicine using tumor metabolism
2011-04-15
PHILADELPHIA—Identifying gene mutations in cancer patients to predict clinical outcome has been the cornerstone of cancer research for nearly three decades, but now researchers at the Kimmel Cancer Center at Jefferson have invented a new approach that instead links cancer cell metabolism with poor clinical outcome. This approach can now be applied to virtually any type of human cancer cell.
The researchers demonstrate that recurrence, metastasis, and poor clinical outcome in breast cancer patients can be identified by simply gene profiling cancer cells that are using ...
Secrets of a precision protein machine
2011-04-15
VIDEO:
Much of the FEN1 structure was solved by Sakurai et al, but how FEN1 works was not apparent in the DNA-free structure. The presence of DNA appears to induce the...
Click here for more information.
DNA replication is critical to the life of all organisms, insuring that each new cell, as well as each new offspring, gets an accurate copy of the genome. Among the legions of proteins that do the work so essential to a cell's survival, the DNA-slicing "flap endonuclease" ...
Colorado Supreme Court to Review Wal-Mart Personal Injury Damages Issue
2011-04-15
The Colorado Supreme Court recently decided to review a 2010 Colorado Court of Appeals decision involving the collateral source rule. The central issue is whether a Colorado personal injury defendant can introduce evidence of the actual amount a health provider received for a plaintiff's injuries.
Under common law, compensation or indemnity paid to an injured party by a collateral source (that is, not the alleged wrongdoer in the lawsuit) does not reduce the damages that could otherwise be recovered from the wrongdoer. In Crossgrove v. Wal-Mart Stores, Inc., a delivery ...
Crash rates may be higher for teen drivers who start school earlier in the morning
2011-04-15
DARIEN, IL – A study in the April 15 issue of the Journal of Clinical Sleep Medicine shows increased automobile crash rates among teen drivers who start school earlier in the morning.
Results indicate that in 2008 the weekday crash rate for 16- to 18-year-olds was about 41 percent higher in Virginia Beach, Va., where high school classes began at 7:20 - 7:25 a.m., than in adjacent Chesapeake, Va., where classes started at 8:40 - 8:45 a.m. There were 65.8 automobile crashes for every 1,000 teen drivers in Virginia Beach, and 46.6 crashes for every 1,000 teen drivers in ...
A safer treatment could be realized for millions suffering from parasite infection
2011-04-15
A safer and more effective treatment for 10 million people in developing countries who suffer from infections caused by trypanosome parasites could become a reality thanks to new research from Queen Mary, University of London published today (15 April).
Scientists have uncovered the mechanisms behind a drug used to treat African sleeping sickness and Chagas disease, infections caused by trypanosome parasites which result in 60,000 deaths each year.
The study, appearing in the Journal of Biological Chemistry, investigated how the drug nifurtimox works to kill off the ...
NYC Bicyclists May Face New Laws, Challenges
2011-04-15
An editorial in the New York Post gave City Councilman Eric Ulrich a "Knucklehead Award" for his proposal to license all bicycles in New York City. Ulrich, from Queens (and the youngest serving member of the council at age 24), proposed the licensing system after receiving complaints from senior citizens who said, according to Ulrich, that bicyclists "scare the hell out of them."
While some rogue cyclists may tarnish the reputation of all riders, cycling is up across the city, with Department of Transportation figures showing the number of everyday bicycle commuters ...
Blood test could predict metastasis risk in melanoma
2011-04-15
PHILADELPHIA — Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
"The rate at which melanoma is increasing is dramatic, and there is a huge number of patients under surveillance," said Harriet Kluger, M.D., associate professor of medicine at Yale University School of Medicine. "Our current method of surveillance includes periodic imaging, which creates ...
Study examines new treatment for recurrent urinary tract infections
2011-04-15
[EMBARGOED FOR APRIL 15, 2011] Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women. A depletion of vaginal lactobacilli, a type of bacteria, is associated with urinary tract infection risk, which suggests that replenishing these bacteria may be beneficial. Researchers conducted a double-blind placebo-controlled trial to investigate this theory. Their results are published in Clinical Infectious Diseases and now available ...
LAST 30 PRESS RELEASES:
New strategies to enhance chiral optical signals unveiled
Cambridge research uncovers powerful virtual reality treatment for speech anxiety
2025 Gut Microbiota for Health World Summit to spotlight groundbreaking research
International survey finds that support for climate interventions is tied to being hopeful and worried about climate change
Cambridge scientist launches free VR platform that eliminates the fear of public speaking
Open-Source AI matches top proprietary model in solving tough medical cases
Good fences make good neighbors (with carnivores)
NRG Oncology trial supports radiotherapy alone following radical hysterectomy should remain the standard of care for early-stage, intermediate-risk cervical cancer
Introducing our new cohort of AGA Future Leaders
Sharks are dying at alarming rates, mostly due to fishing. Retention bans may help
Engineering excellence: Engineers with ONR ties elected to renowned scientific academy
New CRISPR-based diagnostic test detects pathogens in blood without amplification
Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer
Growing solar: Optimizing agrivoltaic systems for crops and clean energy
Scientists discover how to reactivate cancer’s molecular “kill switch”
YouTube influencers: gaming’s best friend or worst enemy?
uOttawa scientists use light to unlock secret of atoms
NJIT mathematician to help map Earth's last frontier with Navy grant
NASA atmospheric wave-studying mission releases data from first 3,000 orbits
‘Microlightning’ in water droplets may have sparked life on Earth
Smoke from wildland-urban interface fires more deadly than remote wildfires
What’s your body really worth? New AI model reveals your true biological age from 5 drops of blood
Protein accidentally lassos itself, helping explain unusual refolding behavior
With bird flu in raw milk, many in U.S. still do not know risks of consuming it
University of Minnesota research team awarded $3.8 million grant to develop cell therapy to combat Alzheimer’s disease
UConn uncovers new clue on what is leading to neurodegenerative diseases like Alzheimer’s and ALS
Resuscitation in out-of-hospital cardiac arrest – it’s how quickly it is done, rather than who does it
A closer look at biomolecular ‘silly putty’
Oxytocin system of breastfeeding affected in mothers with postnatal depression
Liquid metal-enabled synergetic cooling and charging: a leap forward for electric vehicles
[Press-News.org] Experimental drug inhibits cell signaling pathway and slows ovarian cancer growthDrug also increases sensitivity to chemotherapy, may help fight drug resistance, study finds